Antifungal resistance does not necessarily affect Candida glabrata fitness

Journal of Chemotherapy

Volumn 26, Issue 1, 2014, Pages 32-36

  Borghi, Elisa ^a   Andreoni, Stefano ^b   Cirasola, Daniela ^a   Ricucci, Valentina ^a   Sciota, Rita ^a   Morace, Giulia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Azienda Ospedaliera Universitaria Maggiore Della Carita   (Italy)

Author keywords

Candida glabrata; Echinocandin resistance; FKS mutations; Galleria mellonella model

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN;

ANTIFUNGAL RESISTANCE; ARTICLE; BLOOD CULTURE; CANDIDA GLABRATA; CANDIDIASIS; CELL COUNT; CELL SURVIVAL; COLONY FORMING UNIT; CONTROLLED STUDY; FKS1 GENE; FKS2 GENE; GALLERIA MELLONELLA; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPECIES IDENTIFICATION;

CANDIDA GLABRATA,; ECHINOCANDIN RESISTANCE,; FKS MUTATIONS,; GALLERIA MELLONELLA MODEL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DISEASE MODELS, ANIMAL; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGEMIA; GLUCOSYLTRANSFERASES; HUMANS; LARVA; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MOTHS; MUTATION; POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE PROTEINS; SURVIVAL RATE;

EID: 84893114178     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000100     Document Type: Article

References (30)

1. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011;37:291-95.
2. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133-63.
4. Ruan SY, Huang YT, Chu CC, Yu CJ, Hsueh PR. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes. Int J Antimicrob Agents. 2009;34: 236-9.
5. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the Intensive Care Unit. Clin Infect Dis. 2008;46:1206-13.
6. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11:142-51.
7. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nation wide surveillance study. Clin Infect Dis. 2004;39:309-17.
8. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population based surveillance. Antimicrob Agents Chemother. 2010;54: 5042-7.
9. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother. 2008;52:2263-65.
10. Garnacho-Montero J, Diaz-Martìn A, Garcia-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother. 2010;54:3149-54.
11. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-5.
12. Garcia-Effron G. Chua DJ, Tomada JR, DiPersio J, Perlin DS, Ghannoum M, et al. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother. 2010;54:2225-7.
13. Thompson GR, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS, Patterson TF. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother. 2008;52:3783-5.
14. Costa-de-Oliveira S, Marcos Miranda I, Silva RM, Pinto E Silva A, Rocha R, Amorim A, et al. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother. 2011;55:1312-4.
15. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53:3690-9.
16. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother. 2007;51:1876-8.
17. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50:2892-4.
18. owen LE, Kohn LM, Anderson JB. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol. 2001;183:2971-8.
19. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis. 2011;204:626-35.
20. Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without FKS mutations. Antimicrob Agents Chemother. 2012;56:5875-82.
21. rd ed. Approved standard M27-205 A3. Wayne (PA): CLSI; 2008.
22. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third Informational Supplement, M27-S3. Wayne (PA): CLSI; 2008.
23. White TJ, Bruns TD, Lee SB, Taylor JW. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: MA Innis, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: a guide to methods and applications. San Diego (CA): Academic Press, Inc.; 1990. p. 315-22.
24. Fuchs BB, O'Brien E, El Khoury JB, Mylonakis E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence. 2010;1:475-82.
25. Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, et al. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun. 2005;73:3842-50.
26. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY antimicrobial surveillance program (2009).Diag Microbiol Infect Dis. 2011;69:45-50.
27. Williams J, Lye DC. Candida glabrata native tricuspid valve endocarditis by continuous infusion of conventional amphotericin B in a patients with nephrotic syndrome. Int J Antimicrob Agents. 2007;30:192-3.
28. Morace G, Borghi E, Iatta R, Amato G, Andreoni S, Brigante G, et al. Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients. BMC Infect Dis. 2011;11:130.
29. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Ostrosky-Zeichner JH, Rex BD, Alexander BD, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46: 2620-9.
30. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56:4862-9.